Benralizumab (Fasenra)

Fasenra (benralizumab) is covered only as FDA‑approved add‑on maintenance therapy for severe eosinophilic asthma in patients ≥12 years (off‑label uses not covered), with initial approval for 6 months and renewals for 12 months. Coverage requires blood eosinophils ≥150 cells/µL within 6 weeks, ≥3 months of specified prior controller therapy (ICS + anti‑IL‑5 or another controller or an ICS/LABA), objective evidence of uncontrolled asthma (≥2 steroid‑treated exacerbations, ≥1 hospitalization/ED visit, FEV1 <80% predicted, FEV1/FVC <0.80, or worsening with OCS taper), prescription by or consultation with an allergist/immunologist/pulmonologist, dosing per label (30 mg SC q4wk ×3 then q8wk), and reauthorization only after ≥6 months of therapy with documented clinical response and continued ICS use.

"FDA-Approved Indication: Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype."